Can early chemo beat the clock against colon cancer?
NCT ID NCT01460589
First seen Feb 18, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This study looks at whether starting chemotherapy 10 to 14 days after surgery for stage III colon cancer is better than waiting the usual 2 weeks or more. About 300 patients are taking part to see if earlier treatment improves survival and lowers the chance of cancer coming back. The trial also checks for side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jun Seok Park
Daegu, South Korea
-
Kyungpook National University Medical center
Daegu, 41404, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-FU)
What this could lead to
If early chemotherapy works better, it could become a new standard to reduce cancer recurrence and improve survival for stage III colon cancer patients.
What could go wrong
This is a moderate-sized phase 3 trial, but results may not apply to all patients. Early chemo could increase side effects or complications without clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.